, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial, Lancet Diabetes Endocrinol
Because physical exercise increases demand on a weakened heart, measures of exercise tolerance are frequently used to monitor the severity of heart failure
Therefore, pharmacogenetic profiling of the CYP2C9 gene in patients with neurological diseases and psychiatric disorders may help optimize VPA dosage, and prevent ADRs and iatrogenic worsening of the disease
Dysesthesia occurred in 5.1% (4 mg), 12.3% (9 mg), and 12.5% (12 mg) of patients treated with retatrutide, compared to 0.9% with placebo, although this was generally mild to moderate and resolved during treatment
Meye, F